While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. Keeping that in mind, here is one cash-producing company that leverages its financial strength to beat its competitors and two that may face some trouble.

Two Stocks to Sell:

Baker Hughes (BKR)

Trailing 12-Month Free Cash Flow Margin: 8.9%

Tracing lineage to a 1907 cable tool drill bit patent, Baker Hughes (NASDAQ: BKR) provides equipment and services for oil and gas drilling, production, and transport.

Why Does BKR Give Us Pause?

1. Annual sales growth of 6.8% over the last five years lagged behind its energy upstream and integrated energy peers as its large revenue base made it difficult to generate incremental demand
2. Gross margin of 22.1% is below its competitors, leaving less money to invest in exploration and production

Baker Hughes’s stock price of $53.62 implies a valuation ratio of 23.8x forward P/E. Check out our free in-depth research report to learn more about why BKR doesn’t pass our bar.

Core Laboratories (CLB)

Trailing 12-Month Free Cash Flow Margin: 3.5%

With roots dating back to the first commercial oil boom, Core Laboratories (NYSE: CLB) analyzes rock and fluid samples from oil and gas reservoirs to help energy companies optimize production and recovery.

Why Is CLB Risky?

1. Muted 3.4% annual revenue growth over the last five years shows its demand lagged behind its energy upstream and integrated energy peers
2. Smaller revenue base of $524.7 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
3. High extraction costs and unfavorable asset economics are reflected in its low gross margin of 20.4%

Core Laboratories is trading at $11.62 per share, or 1x forward price-to-sales. To fully understand why you should be careful with CLB, check out our full research report (it’s free).

One Stock to Watch:

Stryker (SYK)

Trailing 12-Month Free Cash Flow Margin: 18.1%

With over 150 million patients impacted annually through its innovative healthcare technologies, Stryker (NYSE: SYK) develops and manufactures advanced medical devices and equipment across orthopedics, surgical tools, neurotechnology, and patient care solutions.

Why Do We Like SYK?

1. Core business can prosper without any help from acquisitions as its organic revenue growth averaged 9.2% over the past two years
2. Earnings growth has comfortably beaten the peer group average over the last five years as its EPS has compounded at 12.2% annually
3. Free cash flow margin expanded by 4 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends

At $310.29 per share, Stryker trades at 20.1x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.

High-Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.